PE20220129A1 - Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a - Google Patents

Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Info

Publication number
PE20220129A1
PE20220129A1 PE2021001053A PE2021001053A PE20220129A1 PE 20220129 A1 PE20220129 A1 PE 20220129A1 PE 2021001053 A PE2021001053 A PE 2021001053A PE 2021001053 A PE2021001053 A PE 2021001053A PE 20220129 A1 PE20220129 A1 PE 20220129A1
Authority
PE
Peru
Prior art keywords
docetaxel
cyp3a inhibitor
solid tumors
combination treatment
combination
Prior art date
Application number
PE2021001053A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Original Assignee
Modra Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals B V filed Critical Modra Pharmaceuticals B V
Publication of PE20220129A1 publication Critical patent/PE20220129A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2021001053A 2018-12-21 2019-12-18 Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a PE20220129A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215488 2018-12-21
PCT/EP2019/086125 WO2020127607A1 (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Publications (1)

Publication Number Publication Date
PE20220129A1 true PE20220129A1 (es) 2022-01-27

Family

ID=64901398

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001053A PE20220129A1 (es) 2018-12-21 2019-12-18 Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Country Status (13)

Country Link
US (1) US20220071944A1 (enExample)
EP (1) EP3897611A1 (enExample)
JP (3) JP2022514960A (enExample)
KR (1) KR20220004011A (enExample)
CN (1) CN113473982A (enExample)
AU (2) AU2019410062A1 (enExample)
BR (1) BR112021012266A2 (enExample)
CA (1) CA3124319C (enExample)
CL (1) CL2021001635A1 (enExample)
IL (1) IL284225A (enExample)
MX (1) MX2021007480A (enExample)
PE (1) PE20220129A1 (enExample)
WO (1) WO2020127607A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897610B1 (en) * 2018-12-21 2025-04-16 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
CN116270617B (zh) * 2023-03-29 2024-01-26 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101544498B1 (ko) 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
WO2010020799A2 (en) 2008-08-22 2010-02-25 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
EP3897610B1 (en) * 2018-12-21 2025-04-16 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels

Also Published As

Publication number Publication date
KR20220004011A (ko) 2022-01-11
CA3124319A1 (en) 2020-06-25
WO2020127607A1 (en) 2020-06-25
BR112021012266A2 (pt) 2021-08-31
IL284225A (en) 2021-08-31
AU2023204693A1 (en) 2023-08-10
JP2025094186A (ja) 2025-06-24
MX2021007480A (es) 2021-10-13
JP2022514960A (ja) 2022-02-16
JP2023102786A (ja) 2023-07-25
EP3897611A1 (en) 2021-10-27
AU2019410062A1 (en) 2021-08-12
US20220071944A1 (en) 2022-03-10
CN113473982A (zh) 2021-10-01
CA3124319C (en) 2023-07-04
CL2021001635A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
CO2020014009A2 (es) Inhibidores de mcl-1
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2022010805A (es) Metodo para reducir la neutropenia.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX2018010252A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
MX2017013802A (es) Métodos para tratar el cáncer.
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2019003402A1 (es) Composiciones sólidas para administración oral.
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado